[The immunomodulating effect of sodium nucleinate in chronic infectious-allergic urticaria]. 1990

V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva

Based on clinical, laboratory, bacterial, allergologic and immunologic studies a group of patients with infectious allergic urticaria (IAU) was distinguished. The immunologic examination of 30 patients with IAU identified a decrease in phagocytosis. Sodium nucleinate (SN) was employed as an immunomodulator as compared to placebo. SN was noted to produce an optimal immunomodulating effect, provided it was combined with antibacterial drugs. The use of SN in patients with IAU produced a good clinical effect elucidated for 6 months. It is recommended that SN be used as an immunomodulator in the multimodality therapy of IAU and introduced into the practice of the allergological rooms.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009696 Nucleic Acids High molecular weight polymers containing a mixture of purine and pyrimidine nucleotides chained together by ribose or deoxyribose linkages. Nucleic Acid,Acid, Nucleic,Acids, Nucleic
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
January 1989, Patologicheskaia fiziologiia i eksperimental'naia terapiia,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
January 1981, Terapevticheskii arkhiv,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
January 1990, Journal of hygiene, epidemiology, microbiology, and immunology,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
January 1984, Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Pneumoftiziologia,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
September 1979, Antibiotiki,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
January 1986, Terapevticheskii arkhiv,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
April 1971, Polish medical science and history bulletin,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
April 1971, Polski tygodnik lekarski (Warsaw, Poland : 1960),
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
November 1979, Antibiotiki,
V M Zemskov, and Iu A Poroshina, and L V Luss, and O I Belostotskaia, and G N Mikheeva
May 2003, Annales de dermatologie et de venereologie,
Copied contents to your clipboard!